



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373/35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Date: May 12, 2026

To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street,
Mumbai – 400 001

Ref: -Security Code No.524768
Sub: Outcome of Board Meeting

The Board of Directors at their meeting held today i.e. May 12, 2026 has transacted the following items of business:

Financial Results:

The Board of Directors approved the Audited Standalone Financial Results for the year ended 31.03.2026 along with the Statement of Assets and Liabilities for the year ended 31.03.2026 in the specified format along with the Auditors Report thereon.

The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting(s) held on May 12, 2026.

Enclosed are the Audited statements and declaration on Audit report with unmodified opinion.

The Meeting commenced at 12:20 noon and concluded at 1.50 p.m.

Kindly take the above on record.

For **EMMESSAR BIOTECH & NUTRITION LIMITED**

M S Raghavan Ayyangar
(Managing Director)

Encl: As above



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373/35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Date: May 12, 2026

To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street,
Mumbai – 400 001

Ref: -Security Code No. 524768

**Sub: Declaration on Audit Report with unmodified opinion pursuant to
Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements)
Regulation, 2015**

We hereby declare and confirm that the Statutory Auditors V. Nagarajan & Co., Chartered Accountant(s), FRN No.: 004879N have issued the Audit Report(s) with Unmodified Opinion on the Standalone Audited Financial Results for the quarter and year ended 31st March, 2026.

This declaration is furnished pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take the information on record.

Thanking you,
Yours faithfully,

For **EMMESSAR BIOTECH & NUTRITION LIMITED**

Jeyavel Balaiah Nadar
Chief Financial Officer

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Emmessar Biotech and Nutrition Limited

Report on the Audit of Financial Results

Opinion

We have audited the accompanying financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter and year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- (i) is presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31 March, 2026.


Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA" s) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial results in India under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management and Board of Director's Responsibilities for the Annual Financial Results

These financial results have been prepared on the basis of the annual financial results of the Company. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of



accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.


Auditor's Responsibility for the Audit of Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results to express an opinion on the Statement.
- Materiality is the magnitude of misstatements in the financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial results may be influenced. We consider quantitative materiality and qualitative factors in
 - (i) planning the scope of our audit work and in evaluating the results of our work; and
 - (ii) to evaluate the effect of any identified misstatements in the financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

For V Nagarajan & Co.

Chartered Accountants

FRN: 004879N



A handwritten signature in black ink, appearing to read "Shankar".

Shankar Cherekupally

Partner

M.No. 252304

UDIN: 26252304GODWEO6033

Place: Hyderabad

Date: 12 May, 2026

EMMESSAR BIOTECH & NUTRITION LTD						
Regd Office: Plot No. T-3/2, MIDC, Taloja, Raigad District, Maharashtra - 410 208						
CIN: L24110MH1992PLC06594229						
AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2026					Rs. In lacs	
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2026 Audited	31.12.2025 Unaudited	31.03.2025 Audited	31.03.2026 Audited	31.03.2025 Audited
	PART A					
1	Revenue from Operations	9.28	9.34	9.57	37.08	61.09
2	Other Income	47.34	48.98	60.78	203.58	200.87
	Total Income A (1 + 2)	56.62	58.32	70.36	240.66	261.96
	PART B					
3	Expenses					
	(a) Cost of material consumed	2.76	2.75	4.30	6.24	6.90
	(b) Purchase of Stock-trade	-	-	-	-	12.64
	(c) Change in inventories of Finished goods	0.44	0.79	(1.06)	2.54	(1.36)
	(d) Employee Benefit Expenses	26.31	32.99	21.41	107.91	92.90
	(e) Depreciation & amortisation of Assets	2.51	2.51	2.44	10.01	9.77
	(f) Finance cost	0.06	0.06	0.06	0.25	0.06
	(g) Other Expenditure	16.58	6.38	17.32	55.75	45.24
	Total Expenses (a to f)	48.67	45.47	44.47	182.70	166.15
4	Profit from operations before exceptional items and taxes (A - B)	7.96	12.85	25.89	57.96	95.82
5	Exceptional Items	-	-	-	-	-
6	Profit/ loss before tax (4 - 5)	7.96	12.85	25.89	57.96	95.82
7	Tax Expense					
	i. Current tax	(4.85)	(3.21)	11.30	(17.65)	(27.30)
	ii. Deferred tax asset / (Liability)	0.76	2.01	(0.76)	3.73	(20.16)
	iii. Excess / (Short) provision of earlier years	(0.45)	-	22.21	(0.45)	(16.74)
	Total Tax expense (i+ii+iii)	(4.54)	(1.21)	32.74	(14.37)	(64.20)
8	Net Profit / (loss) after tax (6 - 7)	3.42	11.65	(6.86)	43.59	31.62
9	Less: Other comprehensive income	2.92	-	1.06	2.92	1.06
10	Total comprehensive income for the period and other comprehensive income	0.50	11.65	(7.92)	40.67	30.55
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61
	Face Value of the share	10.00	10.00	10.00	10.00	10.00
	Other equity	-	-	-	311.87	271.20
12	Earnings per Equity Share					
	a) Basic	0.01	0.23	(0.16)	0.81	0.61
	b) Diluted	0.01	0.23	(0.16)	0.81	0.61

NOTES

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 12th May 2026.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS-34) as prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rule 2015 and the Companies (Indian Accounting Standards) Amendments Rule 2016 as amended thereafter.
- During the year the company operated in two segments ie. Healthcare and Rent on leasehold land.
- The audit as required under Regulation 33 of the SEBI (Listing obligation and disclosure agreements) regulations, 2015 has been completed by the Auditors of the company.
- No Investors complaints were received as of Quarter ended 31st March 2026
- Previous years' figures have been regrouped wherever considered necessary.

Place: Mumbai
Date : 12-05-2026

for Emmessar Biotech & Nutrition Ltd



Srinivasa Raghavan Mathurakavi Ayyangar
Chairman & Managing Director.
DIN: 00090266

EIMMESSAR BIOTECH & NUTRITION LTD

CIN: L24110MH1992PLC06594229


Quarter and Year ended Segment wise Revenue Results and
Capital Employed under Clause 41 of the Listing Agreement.

[Rs. In Lacs]

	Quarter ended			Year Ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue (Net Sales/ Income)					
a. Healthcare	9.28	9.34	9.57	37.08	61.09
b. Rent on Leasehold land	41.33	41.33	40.88	165.31	152.36
c. Others	6.01	7.65	19.91	38.27	48.51
Total:	56.62	58.32	70.36	240.66	261.96
Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
Net Sales/ Income from Operations	56.62	58.32	70.36	240.66	261.96
2. Segment Results before Tax and Interest					
a. Healthcare	6.09	5.80	6.33	24.81	39.12
b. Rent on Leasehold land	41.10	41.10	40.65	164.39	151.44
c. Others	6.01	7.65	19.91	38.27	48.51
Total:	53.20	54.55	66.89	227.47	239.07
Less:					
Other Unallocable Expenditure					
Net off Unallocable Income	45.24	41.70	41.00	169.51	143.25
Total Profit / (loss) before Tax	7.96	12.85	25.89	57.96	95.82
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Healthcare	69.27	10.68	13.83	69.27	13.83
b. Rent on Leasehold land	(3.51)	(3.28)	(2.59)	(3.51)	(2.59)
c. Others	745.73	768.46	767.03	745.73	767.03
Total	811.48	775.86	778.27	811.48	778.27

The above results were taken on record at a meeting of the Board of Directors held on 12th May 2026

Mumbai
12th May 2026


 By order of the Board
 Srinivasa Raghavan Mathurakavi Ayyangar
 Chairman & Managing Director
 DIN: 00090266

EMMESSAR BIOTECH & NUTRITION LTD			
CIN: L24110MH1992PLC06594229			
Audited Statements of Assets & Liabilities as on 31st March, 2026			
(Rs. In Lacs)			
	Particulars	As at 31st Mar 2026	As at 31st Mar 2025
A	ASSETS		
1	Non-current Assets		
	(a) Property, Plant & Equipment	113.83	122.06
	(b) Investment Property	57.89	58.83
	(c) Other Financial Assets	0.49	0.49
	(d) Deferred Tax Assets (net)	-	-
	Sub-total Non-current Assets	172.21	181.37
2	Current Assets		
	(a) Inventories	9.72	12.38
	(b) Investments	1.02	0.96
	(c) Trade Receivables	1.65	1.78
	(d) Cash & Cash equivalents	3.34	1.05
	(e) Bank balance other than cash & Cash Equi	728.30	686.13
	(f) Loans	2.42	3.05
	(g) Income tax assets (net)	0.00	-
	(h) Other Financial assets	25.28	25.98
	(i) Other current assets	9.07	9.30
	Sub-total Current Assets	780.80	740.62
	TOTAL ASSETS	953.01	921.99
B	EQUITY AND LIABILITIES		
1	SHAREHOLDER'S FUNDS:		
	(a) Equity Share Capital	499.61	499.61
	(b) Other Equity	311.87	271.20
	Sub-total Shareholder's funds	811.48	770.81
2	Non-current Liabilities		
	(a) Other Financial liabilities	58.38	59.40
	(b) Long Term Provisions	16.87	13.05
	(c) Deferred Tax Liability (net)	27.77	31.49
	Sub-total Non-current liabilities	103.02	103.94
3	Current Liabilities		
	(a) Borrowings	-	-
	(b) Trade payables	0.63	0.33
	(c) Other financial Liabilities	11.49	9.29
	(e) Other current liabilities	3.48	3.56
	(f) Short-term provisions	22.92	34.06
	Sub-total Current Liabilities	38.52	47.24
	TOTAL EQUITY AND LIABILITIES	953.01	921.99

EMMESSAR BIOTECH & NUTRITION LTD

CIN: L24110MH1992PLC06594229

Rupees in Lacs

CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2026		2025-26	2024-25
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit before Tax and Extraordinary Items	57.96	95.82
	Add/(-)Less: Depreciation	10.01	9.76
	Interest/ Dividend	-38.31	-45.60
	Other comprehensive income	-4.04	-1.46
	Operating Profit / Loss before working Capital changes	25.62	58.53
	Adjustment for (Increase)/ Decrease in operating Assets		
	Inventories	2.65	-3.46
	Trade Receivables	0.13	0.45
	Non current loans and Income Tax Assets	-19.99	-19.78
	Current Assets - Loans and other assets	0.85	-1.34
	Adjustment for Increase / (Decrease) in operating Liabilities		
	Non current provisions	3.82	2.14
	Trade Payables	0.30	-0.58
	Borrowings and Other Financial Liabilities	-2.19	-11.71
	Other Current Liabilities	-0.25	2.01
	Current Provisions	3.72	-2.23
	Cash generated before tax payments	14.66	24.04
	Add: Direct Tax Paid (Net of Refund)	0.00	-1.65
	Less: Income tax paid	11.85	0.00
	Cash generated from operations	26.51	22.39
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	-0.85	0.00
	Investments in Mutual Funds	-0.06	-0.07
	Interest / Dividend Received	35.70	46.24
	Investments in Fixed Deposits (maturing within 12 months)	-60.43	-69.16
	Deposits Received	0.00	0.00
	Net Cash inflow/(out flow) in Investing activities	-25.66	-22.98
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Net Cash used in financing activities		
	Interest Expense on Security Deposit	-0.25	-0.06
	Interest Income on Security Deposit	1.67	0.41
	Net Cash inflow/(out flow) in Financing activities	1.42	0.35
	Net increase in cash and cash equivalents	2.29	-0.24
	Cash and cash equivalents as at the beginning of the year	1.05	1.29
	Cash and cash equivalents as at the end of the year	3.34	1.05

[Handwritten Signature]